ScoutQuest17 Nov 2026
Laurus Labs540222Analyst view

ICICI Securities rates Laurus Labs Ltd Buy

BUY, target ₹2555, based on 38x FY29E EBITDA of ₹3686 crore.

By ScoutQuest · · 1 min read

Report date
17 Nov 2026

From the report

The figures below are as printed in the report by ICICI Securities.

Rating
Buy
Target
₹ 2550
Price at report
₹ 2215
Upside to target
15.1%from the price at report, worked out from the two figures above
Valuation
38 x · EV/EBITDA · FY29E
Report
company update
Horizon
12 months

The broker values the stock at 38x FY29E EBITDA of ₹3686 crore, judging the premium justified by the sustained capex drive and consistent delivery.

Catalysts

The broker's points, summarised.

  • Continued CDMO growth and commercial supply visibility over 18–24 months
  • Peptide validation batches and subsequent commercial revenues
  • Laurus Bio-4 commercial fermentation facility commissioning and supplies from Q1FY28
  • KRKA JV formulation facility ramping up with revenue in FY28–FY29
  • Large capex (₹3,000 crore FY27–FY28 and Laurus Pharma Zone) driving the next growth leg

Risks

The broker's points, summarised.

  • Overall performance heavily dependent on CDMO success
  • Non-ARV, non-CDMO businesses remain volatile

Analysts: Siddhant Khandekar, Shubh Mehta, Vedant Nilekar

CDMO expansion drives revenue and mix

ICICI Securities notes Q2FY27 revenue of ₹2,206 crore grew 33% YoY, led by CDMO revenue of ₹875 crore, up 86% YoY. The CDMO quarterly run rate has risen from ₹220–250 crore to about ₹800 crore in two years.

Margin expansion reflects favourable mix

EBITDA was ₹750 crore at a 34% margin, up 962 bps YoY, as gross margin improved 314 bps to 63%. PAT reached ₹437 crore on better product mix and operating leverage.

Capex focus tilts toward CDMO

Of ₹5,180+ crore capex in FY22–27, about 84% was earmarked toward API/CDMO, and the ₹3,000 crore FY27/FY28 guidance is CDMO-tilted. Management targets CDMO at ~50% of revenue by FY30.

CDMO growth is broad based

About 55% of CDMO revenue came from commercial supplies and the rest from late-stage clinical projects, supporting run-rate sustainability. ICICI Securities cites visibility on commercial supplies over the next 18–24 months.

ICICI Securities's call

ICICI Securities maintains a BUY rating with a target price of ₹2,555. It holds this view because it sees CDMO-led growth and sustained capex execution as justifying a premium. The target uses 38x FY29E EBITDA of ₹3,686 crore.

Source: ICICI Securities · 17 Nov 2026

The call above is ICICI Securities's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev